Sue Gail Eckhardt Sells 9,812 Shares of Exelixis (NASDAQ:EXEL) Stock

Posted by on Jun 5th, 2026

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Sue Gail Eckhardt sold 9,812 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $806,201.06. The trade was a 37.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Exelixis Trading Up 1.7%

Shares of NASDAQ:EXEL opened at $52.49 on Friday. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $52.96. The company has a market cap of $13.19 billion, a PE ratio of 17.44, a price-to-earnings-growth ratio of 1.08 and a beta of 0.41. The company’s 50 day moving average is $46.76 and its 200 day moving average is $44.47.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. Equities research analysts predict that Exelixis, Inc. will post 3.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EXEL has been the topic of several recent research reports. Stifel Nicolaus upped their price target on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Morgan Stanley upped their target price on Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Finally, Wells Fargo & Company lifted their price target on Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.35.

Check Out Our Latest Research Report on Exelixis

Institutional Trading of Exelixis

Several institutional investors have recently modified their holdings of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Exelixis by 4.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after buying an additional 68,133 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after acquiring an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC lifted its position in shares of Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after acquiring an additional 2,764 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Featured Stories

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.